Dr. Joyce Elizabeth Feagin, MD

Dr. Feagin practices at WK Hematology Oncology Associates in Shreveport, Louisiana.

Dr. Feagin's NPI, 1285660316, was assigned on June 23, 2006. Dr. Feagin graduated from Frederick P. Whiddon College of Medicine in 1994. Dr. Feagin's Louisiana license number on file is 13709R.

Dr. Feagin's primary practice is WK Hematology Oncology Associates, at 2600 Kings Hwy, Shreveport, LA 71103 in Caddo Parish. The practice phone is (318) 212-8620.

Dr. Feagin's primary practice is WK Hematology Oncology Associates in Shreveport, Louisiana. Dr. Feagin is also affiliated with Willis Knighton North. The medical group on file is Willis Knighton Genetics. Dmand AI also links Dr. Feagin to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feagin practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Feagin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Feagin is board certified in hospice and palliative medicine by the American Board of Internal Medicine. Dmand AI has Dr. Feagin's licenses on file in 2 states: Louisiana and Alabama.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances, immune deficiency disease and lung cancer among the conditions Dr. Feagin treats.

CMS data shows 1,299 Medicare services from Dr. Feagin across 8 procedure codes in 2024, for 366 Medicare patients. Medicare paid $75,616 for them.

CMS counts 366 Medicare patients who saw Dr. Feagin in 2024. The largest group is 75 to 84, with 152 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feagin's median patient age at 71, with 77% women.

In 2024, Dr. Feagin wrote 1,388 Medicare Part D claims for 190 patients. 84% of them were for generic drugs. CMS names the drug for 1,064 of them, across 34 drugs with 11 or more claims each, at $2,458,880 in total drug cost. In 2023, CMS named 838 claims across 25 drugs.

Dr. Feagin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Feagin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse and Lymphoma, B-Cell.

CMS Open Payments shows 256 general payments to Dr. Feagin from 40 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 58% of the total. AstraZeneca Pharmaceuticals LP paid the most, $11,121.

Dr. Feagin serves on Pain Committee, Supportive Oncology and Cancer Committee.

Dr. Feagin graduated from Frederick P. Whiddon College of Medicine in 1994. Dr. Feagin is a member of ASCO.

Dr. Feagin is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.